C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients

Elisa Kankkunen, Patrick Penttilä, Katriina Peltola, Petri Bono

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalActa Oncologica
Volume61
Issue number10
Pages (from-to)1240-1247
Number of pages8
ISSN0284-186X
DOIs
Publication statusPublished - 3 Oct 2022
MoE publication typeA1 Journal article-refereed

Fields of Science

  • Nivolumab
  • C-reactive protein
  • immune-related adverse event
  • biomarker
  • metastatic renal cell carcinoma
  • TO-LYMPHOCYTE RATIO
  • NIVOLUMAB
  • CANCER
  • ASSOCIATION
  • SURVIVAL
  • Metastatic renal cell carcinoma
  • Biomarker
  • Immune-related adverse event
  • 3122 Cancers

Cite this